cipla: Analysts lower targets on Cipla

0

Mumbai: Analysts have trimmed their price targets on by 1-4% after the drugmaker reported lower-than-expected earnings for the December quarter.

They were also disappointed with the margin guidance of 21-22% for the ongoing financial year. Shares of Cipla ended up 1.2% to close at ₹937.50 on Wednesday, recovering from early losses.

CLSA, Jefferies and

maintained a buy rating, Credit Suisse retained an outperform, and Morgan Stanley remains overweight on the stock post results.

Agencies

“While the stock lacks immediate catalysts, a strong pipeline in the US starting in the second half of FY23 keeps us constructive, along with Cipla’s strong positioning in India and South Africa,” said CLSA. “We believe a 21 times FY24 price to earnings valuation is fair given Cipla’s long-term growth prospects and a favourable base for its US business,” the brokerage said.
has downgraded the stock to add from buy. “We cut our revenue and EPS estimates by 2% and 6-9% respectively to factor-in declining covid sales and higher costs,” said ICICI Securities.

FOLLOW US ON GOOGLE NEWS

 

Read original article here

Denial of responsibility! TechnoCodex is an automatic aggregator of the all world’s media. In each content, the hyperlink to the primary source is specified. All trademarks belong to their rightful owners, all materials to their authors. If you are the owner of the content and do not want us to publish your materials, please contact us by email – [email protected]. The content will be deleted within 24 hours.

Leave a comment